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Acetylcholine (Ach) could serve as a selective renal
medullary vasodilator in studies of the mechanism of
arterial pressure regulation; however, effects of
intramedullary Ach infusion were disparate. In anesthetized
rats, the total renal blood flow (RBF) was measured by renal
artery probe, and local perfusion of the cortex (CBF), outer
medulla (OMBF) and inner medulla (IMBF) as laser-Doppler
(l-D) flux. Renal artery infusion of Ach (60–150 lg/kg/h)
significantly increased RBF by 17% and l-D parameters by
7–14%, without affecting arterial blood pressure (BP); the
responses were prevented by inhibition of nitric oxide (NO)
synthesis with Nx-nitro-L-arginine methyl ester (L-NAME).
Intramedullary Ach (180 lg/kg/h) significantly increased
OMBF by 9% and IMBF by 7% but also RBF and CBF (both
9%). Carbamylcholine (Cch, 15 or 30–60 lg/kg/h), a stable
Ach analog, increased CBF, OMBF, and IMBF by 5–8%; there
was no dose dependency and, as with Ach, no preferential
effect on medullary perfusion. Intramedullary infusion of
prostaglandin E2 (PGE2) (15 lg/kg/h), and S-nitroso-N-acetyl-
D,L penicillamine (SNAP), an NO donor (15–30 mg/kg/h),
significantly and substantially increased OMBF and IMBF
only. Ach increased perfusion of all kidney zones by an
NO-dependent mechanism. Infusion of Ach or Cch into the
renal medullary interstitium failed to affect preferentially the
medullary perfusion, in contrast to the well-demonstrable
selective effects of PGE2 and SNAP. The reason was
probably the Ach’s dual opposed action, vasoconstrictor
and vasorelaxant, on the intrarenal vasculature.
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Acetylcholine (Ach) receptors have been localized in the renal
vascular endothelium and possibly also in the vascular
smooth muscle or pericytes of the vasa recta.1–3 However,
early studies failed to provide evidence for the role of
cholinergic nerves in the control of renal circulation.4–6 Renal
arterial infusion of Ach was reported to induce vasodilatation
and natriuresis;4 however, neurotransmitters normally access
the vessels from the abluminal side, and the effects of
intravascular application of Ach are of pharmacologic interest
only. On the other hand, if targeted administration of Ach to
the medullary tissue resulted in local selective vasodilatation,
the agent would be of potential value in the studies of the
pathogenesis of arterial hypertension. Increasing evidence
indicates that intrarenal circulation, especially perfusion of
the medulla, is linked to the long-term control of arterial
pressure.7,8
Only few attempts were made to infuse Ach into renal
medullary tissue with an aim to increase selectively the renal
medullary but not cortical perfusion. For reasons that were
not clear, the results of studies in the rat were disparate8,9 and
those in the rabbit were not successful.10
In this study, we examined thoroughly the effects of
administration of Ach and carbamylcholine (Cch), its stable
analog, directly to the renal medullary interstitium and
examined effects on the perfusion of the cortex and outer and
inner medulla. The results were compared with effects of
intramedullary infusion of prostaglandin E2 (PGE2) and a
nitric oxide (NO) donor compound S-nitroso-N-acetyl-D,L
penicillamine (SNAP), the two vasodilator agents whose
action is independent of NO synthesis.
RESULTS
During renal artery infusion of Ach at 60 mg/kg/h, the
systemic arterial blood pressure (BP) remained stable at
12271 mmHg, and with the dose of 150 mg/kg/h it was
11972 and 11872 mmHg in the control period and during
the infusion, respectively. Ach in the dose of 30 mg/kg/h did
not change BP, cortex blood flow (CBF), or inner medulla
blood flow (IMBF) significantly (Figure 1).
The effects on renal hemodynamics did not differ between
the doses of 60 and 150 mg/kg/h and the data are presented
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jointly. Both the renal artery blood flow (RBF) and the three
laser-Doppler flux parameters, CBF, outer medulla blood
flow (OMBF), and IMBF, increased significantly. The increase
developed within less than 10 min, followed by a plateau.
After discontinuation of infusion, a prompt recovery to
baseline was seen. A comparison of percent increases in the
hemodynamic parameters (Figure 1b) shows that there were
no substantial differences in the response to Ach between
individual laser-Doppler parameters, which increased by
6–14%; RBF increased by 17%.
In two separate series (protocols 2 and 4, Materials and
Methods), we examined effects of inhibition of NO synthesis
on renal hemodynamic responses to Ach. L-NAME per se
(pooled data from the two series, n¼ 14, for IMBF n¼ 7)
modestly increased BP by 872% (Po0.02) and very
substantially and significantly decreased RBF (3672%),
CBF (1972%), OMBF (3974%), and IMBF (2775%).
Renal hemodynamic responses to renal arterial infusion of
Ach were markedly blunted by L-NAME pretreatment
(Figure 2).
During renal medullary interstitial infusion of Ach at 60
or 180 mg/kg/h, the BP remained stable at 11173 and
11372 mmHg, respectively. During Cch infusion, at 15 or
30–60 mg/kg/h, the BP remained constant at 12072 or
11772 mmHg, respectively. During intramedullary PGE2
infusion, the BP was 11571 mmHg, compared to
11471 mmHg in the control period. During renal medullary
infusion of SNAP, the mean BP decreased significantly from
13274 to 12174 mmHg.
When there was an increase in any of the renal perfusion
parameters after intramedullary Ach or Cch, it took at least
10 min to develop, and after discontinuation of the infusion,
the recovery to baseline lasted about 15 min, substantially
longer than after renal artery infusion of the drug; similar
dynamics of the responses was observed in the case of PGE2.
In the case of SNAP, the onset of action and the recovery
tended to be more rapid than with the other drugs.
The responses of renal hemodynamic parameters to
intramedullary infusion of Ach and Cch (two doses of each),
of PGE2 and SNAP, are presented in Table 1 and the percent
changes in RBF, CBF, and IMBF after Ach and Cch are shown
in Figure 3. The low-dose Ach did not affect renal
hemodynamics but when the dose was tripled, the mean
RBF, CBF, OMBF, and IMBF values increased significantly
(Table 1 and Figure 3).
Cch distinctly increased the mean renal hemodynamic
variables at a dose of 15 mg/kg/h, that is, more than 10-fold
lower than the active dose of Ach. At the doses of 15, 30, and
60 mg/kg/h, the increase in RBF, CBF, OMBF, and IMBF was
similar; no dose dependency was seen. The mean increases in
all the perfusion parameters in response to 15 and 30–60 mg/
kg/h were significant when tested by the paired Student’s
t-test (Table 1 and Figure 3).
Intramedullary infusion of PGE2 and SNAP substantially
and significantly increased OMBF and IMBF (Table 1). RBF
and CBF decreased moderately after PGE2, whereas after
SNAP the RBF decreased slightly (less than 5%) and CBF
did not change. There was no difference in the response to
SNAP dose of 5 and 10 mg/kg/h and the data were analyzed
jointly.
In the case of PGE2 and SNAP, the responses of the
perfusion variables distinctly differed between the cortex and
medulla: a substantial significant increase occurred in the two
medullary zones only. This was not so in the case of Ach and
Cch; here the mean increases were similar and significant in
all kidney zones. Moreover, a closer inspection of the data
showed that the mean increases in Ach-2, Cch-1, and Cch-2
groups were because of substantial individual increases
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Figure 1 | Renal artery infusions of Ach. Effects on total RBF, and on
the CBF, OMBF, IMBF. Means7s.e.m. Data for nine preliminary
experiments with Ach dose of 30 mg/kg/h (only CBF and IMBF
measured) and 25 experiments with Ach dose of 60–150mg/kg/h
(IMBF measured in 10 experiments); n values are given in
parentheses. (a) (left panel) Absolute values for nine Ach-30 studies
(dotted lines) and 25 Ach 60–150 studies (solid lines). Within the latter
group, IMBF was measured in 10 experiments only. (b) (right panel) %
changes from pre-Ach control. *Significantly different from control by
paired Student’s t-test.
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Figure 2 | Renal artery infusion of Ach at 60 lg/kg/h: effects on
RBF, CBF, and OMBF in seven rats untreated (blank columns) and
then after L-NAME treatment (1.8 mg/kg intravenously) (black
columns). *Significantly different from pre-Ach control (paired
Student’s t-test); wdifferent from the change in untreated rats
(unpaired Student’s t-test).
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(of 5% or greater) in a limited percentage of experiments,
30–74% for different drug doses and parameters; in other
tests, no change or (rarely) increases of less than 5%
were seen.
In order to reject with more certainty the possibility of a
preferential vasodilator action of Ach and Cch in the
medulla, the responses of the hemodynamic parameters to
PGE2, Ach, and Cch were further analyzed with respect to the
frequency with which the increases (of 5% or greater)
occurred in the cortex and outer and inner medulla, relative
to the total number of tests performed (Figure 4). In the case
of PGE2, the increases in OMBF and IMBF of 5% or more
occurred in almost 80% of tests, whereas the increases in RBF
and CBF occured in 6% of tests only. In the case of Ach and
Cch, the pattern was different: the increases in the parameters
of medullary perfusion were not more frequent than those in
RBF and CBF.
The frequency distribution of the increases was analyzed
by w2 statistics. In order to ensure the credibility of the
analysis, which depends critically on the number of
observations, the Cch (rather than Ach) tests were analyzed
and compared with those for PGE2; moreover, the OMBF
and IMBF data were pooled. After PGE2 infusion, OMBF or
IMBF increased in 78% of tests. This frequency was
significantly higher than random (50%) frequency
(w2¼ 10.12, Po0.005).
In the case of Cch, the frequency of increases in medullary
perfusion (OMBF and IMBF) was 42%, which was not
significantly different from the random distribution
(w2¼ 1.7, 0.1oPo0.2). The frequency of increases in
medullary blood flow (MBF) between PGE2 (78%) and
Cch (42%) was also found to be significantly different
(w2¼ 10.04, Po0.005).
Effects of inhibition of NO synthesis with L-NAME on the
renal hemodynamic responses to intramedullary Ach are
presented in Table 2 and a comparison of the respective
percent changes is shown in Figure 5. The control data
obtained before L-NAME administration confirmed a fairly
uniform increase in the perfusion of all renal zones shown
earlier in Table 1 and Figure 3. The two sequential doses of
L-NAME decreased the baseline perfusion parameters by
about 20–35% (Table 2). The pretreatment reduced the
response to Ach; however, in the case of RBF, a significant
increase persisted after the first L-NAME dose. An intergroup
comparison showed that only in the case of IMBF was the
Table 1 | Effects of intramedullary infusion of Ach, Cch, PGE2 and NO donor (SNAP) on the renal hemodynamics
RBF (ml/min) CBF (PU) OMBF (PU) IMBF (PU)
Control Drug Control Drug Control Drug Control Drug
Ach-1 (9) 7.870.4 7.970.4 673739 672739 — — 165717 165718
Ach-2 (22) 8.070.4 8.870.4* 652726 710726* 178720 195721* 15879 16777*
Cch-1 (21) 8.570.4 9.170.4* 595727 629747* 186712 198720* 14878 15779*
Cch-2 (20) 8.270.3 9.070.3* 591720 621720* 16478 17879* 135712 144715*
PGE2 (16) 9.070.4 8.170.3* 642715 603719* 12877 156711* 117710 143714*
SNAP (8) 5.070.2 5.270.2* 499723 496722 182764 228785* 9677 112711*
Means7s.e.m. RBF, total renal blood flow; CBF, OMBF, IMBF, cortical, outer, inner medullary laser-Doppler flux, respectively; PU, perfusion units; the number of rats tested in
each group is given in parentheses; for OMBF in the Ach-2 series, n=9 and not 22.
*Significantly different from control at Po0.05.
Doses: Ach-1: 60 mg/kg/h; Ach-2: 180 mg/kg/h; Cch-1: 15 mg/kg/h; Cch-2: 30–60 mg/kg/h; PGE2: 15 mg/kg/h; SNAP: 15–30 mg/kg/h.
Ach, acetylcholine; Cch, Carbamylcholine; PGE2, prostaglandin E2; NO, nitric oxide; SNAP, S-nitroso-N-acetyl-D,L penicillamine.
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Figure 3 | Intramedullary infusion of two doses of Ach and Cch: a
comparison of % changes in renal hemodynamics. Ach-1: 60 mg/
kg/h; Ach-2: 180 mg/kg/h; Cch-1: 15 mg/kg/h; Cch-2: 30-60 mg/kg/h.
n values are given in Table 1. *Significant change from control by
paired Student’s t-test.
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Figure 4 | Effects of intramedullary infusion of PGE2, Ach, and
Cch: frequency distribution of increases in renal hemodynamic
parameters. Individual increases of 5% or greater were selected from
the data summarized in Table 1 (PGE2, Ach-2, Cch-1,2). The %
contribution of the increases and their numbers (shaded column
segments) are shown. The number of ‘no-increase’ (o5%) studies is
also shown (blank column segments). See the text for the associated
w2 statistics. The distribution pattern for PGE2 indicates a preferential
vasodilator effect in medullary zones (OMBF, IMBF); there is no
preferential effect in the case of Ach or Cch.
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Ach-induced increase significantly less in L-NAME-pretreated
compared to untreated rats (Figure 5).
DISCUSSION
As expected, renal artery infusions of Ach at the dose that did
not alter systemic arterial pressure increased perfusion of the
kidney; the effect was virtually abolished by pretreatment
with L-NAME. Our experiments extended the available
information by showing that Ach-dependent hyperperfusion
occurred in all kidney zones, from superficial cortex to inner
medulla. These data served as a quasi-control in the studies
designed to examine if Ach applied directly into the renal
medullary interstitium would induce selective medullary
vasodilatation. Given the postulated role of the renal medulla
in long-term control of arterial pressure and body fluid
homeostasis,7,8 selective or preferential medullary vasodila-
tion would provide a valuable tool with which the regulatory
role could further be explored. In addition, we compared the
effects of intramedullary Ach and its stable analog, Cch, with
those of PGE2 and SNAP, an NO donor, the two latter
substances being independent in their action of the
endogenous NO synthesis.
We were unable to establish a dose of intramedullary Ach
that would increase the perfusion of the medulla selectively;
the active doses increased mean RBF, CBF, OMBF, and IMBF
similarly; the responses were remarkably variable.
The reasons for the failure of intramedullary Ach to
increase the local perfusion selectively are not clear. As the
dose applied did not affect arterial BP, any major leakage of
Ach to systemic circulation was unlikely. In order to exert its
action on the cortical vasculature, the drug must have
diffused from the medulla toward the cortex, via the
interstitium, or was carried there with the blood in the
ascending vasa recta.11 However, the effect in the cortex
would then be smaller than in the medulla, depending on the
expected smaller Ach concentration in the former zone.
One of the reasons for the variability of responses to
intramedullary Ach and a failure to obtain differential effects
on the perfusion of the renal medulla vs cortex could be
related to the known in vivo instability of Ach, which is
rapidly broken down by tissue cholinesterase. However, as
was the case with Ach, the responses to Cch, a stable analog
of Ach, were also highly variable and we failed to find a dose
that would induce a selective medullary hyperperfusion. This
was confirmed by the analysis of the frequency of increases in
the perfusion of different kidney zones using w2 statistics. The
pattern of the response to Cch contrasted with the clearly
preferential action of intramedullary PGE2 and SNAP on the
perfusion of the medulla.
The reason for the different profile of responses to
intramedullary infusion of PGE2 and SNAP (a preferential
effect on medullary perfusion) relative to Ach or Cch (no
evidence of a preferential effect) remains unclear. Mattson
et al.9 reported first no selective increase in the perfusion of
the renal papilla in response to an intramedullary infusion of
Ach in anesthetized rats and, in a later study with conscious
unilaterally nephrectomized rats, a selective medullary
vasodilatation was seen.8 However, Ach effects were not the
focus of their studies and no attempt was made to explore the
problem further. Intramedullary Ach tended to increase
slightly the perfusion of the medulla in the rabbit (not
significant), whereas there was a clear increase in total RBF;10
reasons related to differences in the structure of the renal
medulla between the rabbit and rat were invoked to explain
the absence of a preferential effect on the medulla. However,
the present study showed that, also in the rat, an intra-
medullary infusion of two agonists of cholinergic receptors
failed to increase preferentially perfusion of the medulla. In
an attempt to explain this failure, the evidence for a dual
action of Ach will be considered.
In addition to the well-established vasodilator action
mediated by NO released from the vascular endothelium, Ach
can cause vasoconstriction, probably dependent on activation
Table 2 | Effects of intramedullary Ach infusion in rats untreated or pretreated with one or two sequential doses of L-NAME
RBF (ml/min) CBF (PU) OMBF (PU) IMBF (PU)
Control Ach Control Ach Control Ach Control Ach
No treatment (9) 8.170.7 9.170.9* 632730 692735* 178720 195721* 131711 14679*
L-NAME-1 (7) 5.270.7 5,570.7* 507734 535739 121712 128713 8874 9074
L-NAME-2 (5) 5.570.9 5.871.0 495744 513746 112713 119711 8174 8575
Means7s.e.m. *Significantly different from pre-Ach control. Other denotations are as in Table 1.
Ach dose: 180 mg/kg/h; L-NAME-1.2: 1.2 mg/kg.
Ach, acetylcholine; CBF, cortex blood flow; IMBF, inner medulla blood flow; L-NAME, No-nitro-L-arginine methyl ester; OMBF, outer medulla blood flow; RBF, renal artery blood
flow.
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Figure 5 | Intramedullary infusion of Ach at 180 lg/kg/h: a
comparison of % changes in intrarenal hemodynamics in
response to Ach administered before and after two sequential
doses of L-NAME (nine rats). Blank columns – before L-NAME; two
shaded columns – after two sequential doses of L-NAME, 1.2 mg/kg
each. *Significantly different from pre-Ach control when tested by
paired Student’s t-test. wSignificantly different from the change after
Ach alone when tested by unpaired Student’s t-test; n values are
given in Table 2.
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of muscarinic receptors in the smooth muscle cell.12 In their
study of isolated descending vasa recta, Yang et al.3 showed
that in the absence of preconstriction induced by norepi-
nephrine, abluminal administration of Ach caused vasocon-
striction, which suggested the presence of such receptors on
the pericytes. By contrast, in the vessels preconstricted with
norepinephrine, Ach caused an NO-dependent vasodilata-
tion, in accordance with the response seen in other isolated
vessel preparations.13–15 During administration of Ach into
the medullary interstitium, the pericyte, possibly carrying
muscarinic receptors mediating vasoconstriction, would be
better accessible than the endothelium generating NO, and
the vasoconstrictor component could effectively oppose the
endothelium-dependent vasodilatation. Moreover, an early
report suggested that high Ach doses induced vasoconstric-
tion, in contrast to low doses inducing vasodilatation.16
Thus, infusion into the medullary interstitium would provide
a good access of Ach to pericytes carrying muscarinic
receptors and the locally achieved high concentration of the
agent (substantially higher than in the cortex) would lead to a
vasoconstrictor effect that could effectively oppose vasodila-
tation. Therefore, the net vasodilatation would not be greater
than in the cortex. In addition, an evidence was recently
presented from a mouse study that Ach initiates two
competing responses in the endothelium of isolated arteries:
an NO-dependent vasorelaxation and a contraction mediated
by thromboxan A2. If the latter mechanism exists in the rat,
an explanation of our results with Ach becomes even more
complex.17
As expected, we found that the vasodilator effect of renal
artery infusion of Ach on the perfusion of the cortex and
medulla was prevented by an inhibition of NO synthesis. On
the other hand, in the case of intramedullary Ach infusion,
this effect was clearly seen in the inner medulla only. In the
case of the total RBF, CBF, and OMBF, some alleviation of the
response to Ach was seen. One could speculate that the effect
was demonstrable only when the initial Ach concentration
was high, as expected in the medulla during intramedullary
infusion.
Effects of intramedullary infusion of PGE2 and SNAP have
not been described before. The results showed that, unlike
Ach, both substances induced selective medullary vasodilata-
tion and thereby are of potential value as tools in the study of
the link of medullary perfusion and arterial pressure control.
An interesting finding of the present study was that after
intramedullary PGE2, parallel with medullary hyperperfu-
sion, a modest but significant decrease in RBF and CBF was
seen. As the systemic arterial pressure did not decrease, this
effect was not dependent on a reduction of renal perfusion
pressure associated with imperfect autoregulation. An appro-
priately focused study would be needed to explain the
mechanism of this ‘redistribution’ of intrarenal circulation.
Conclusions
The data provide an indirect evidence from an in vivo study
for a dual, vasodilator and vasoconstrictor effect of Ach on
the intrarenal vasculature. This duality of action was probably
the reason why neither Ach nor Cch, its stable analog,
induced selective or preferential medullary vasodilatation
when the agents were applied into the renal medullary
interstitium. This was in contrast to a selective vasodilator
effect of PGE2 and an NO donor compound (SNAP).
MATERIALS AND METHODS
The experimental procedures were approved by the extramural
Regional Ethical Committee (Warsaw). Male Wistar rats weighing
280–330 g, maintained on dry pellet diet and given free access to
water, were anesthetized with intraperitoneal thiopentabarbital
(Thiopental, Biochemie GmbH, Vienna, Austria), 100 mg/kg/body
weight. Throughout the surgical preparation and experimental
procedures, body (rectal) temperature was maintained at 371C by
means of a servo-controlled heating pad. The details of experimental
techniques were described previously.18,19 Briefly, the left kidney was
exposed from a subcostal flank incision and placed in a plastic
holder similar as that used for micropuncture experiments. In
experiments involving an infusion into the left renal artery, a knee-
bent 30-gauge stainless steel cannula, connected with a soft silastic
infusion tubing, was used to puncture the aorta just opposite the
origin of the left renal artery, then the cannula’s tip was manipulated
into the artery lumen. Isotonic saline infusion at a rate of 2 ml/h was
started immediately to keep the infusion line patent. In experiments
involving administration of drugs into the renal medullary
interstitium, a 26-gauge stainless steel cannula was inserted into
the kidney to a depth of 5.5 mm, close to the outer–inner medullary
junction; saline solvent or drug volume infusion rate was 1 ml/h.
Blood flow measurements
The total RBF was measured using a non-cannulating probe, 1 mm
in diameter, placed on the renal artery and connected to a Transonic
flowmeter (type T106, Transonic Systems Inc., Ithaca, NY, USA);
RBF provided an index of cortical perfusion, in addition to the laser-
Doppler cortical flux (CBF) measured using a Perimed, PF 407
probe placed on the kidney surface. We established previously that
experimentally induced changes of the total RBF and CBF were
strictly correlated.20 The outer and inner medullary blood flow
(OMBF, IMBF) was measured as laser-Doppler flux, using two
needle probes (PF 402) inserted into the kidney to a depth of 3 and
5 mm, respectively. All the probes were connected to a laser-Doppler
flowmeter (Periflux 4001, Perimed, Jarfalla, Sweden). The system
measures the laser-Doppler flux, a product of the number of blood
cells moving and of their mean velocity, within an area of less than
1 mm3 beneath the probe tip. Under routine experimental condi-
tions used in the present study, the records of both RBF and laser-
Doppler fluxes of medullary zones were repeatedly shown to be
stable for at least 2 h.18,20,21 The studies in which the recorded
baselines were not stable were abandoned. More often, the baseline
for one out of four simultaneously measured flow parameters was
unstable (e.g. IMBF), then the data for this parameter only
were discarded. In practice, when all or most of baseline records
have stabilized, control measurements were taken, and averaged
over about 15 min. Thereafter, the drug solvent infusion was
replaced by drug infusion; this was continued until stabilization
of the parameters at a new level. Subsequently, the solvent infusion
was resumed, and recovery measurements were taken. Quite
often, another dose of the drug was subsequently tested in a
similar way.
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After experiments, the position of the intrarenal probes and of
the infusion needle was checked at the kidney’s cross-section.
Experimental protocols
I. Effects of renal artery infusion of Ach. Ach (Sigma Chemical
Co., St Louis, MO, USA) was infused at the rate of 30 (nine rats), 60,
or 150mg/kg/h (25 rats). The drug infusion lasted 20–30 min, and
was preceded and followed by solvent (isotonic saline) infusion; the
volume infusion rate was always 1 ml/h (about 0.2% of renal artery
blood flow). The drug solvent infusion did not change renal
perfusion parameters or diuresis. As effects of Ach rapidly returned
to baseline after discontinuation of drug infusion, in most rats two
or three doses, given at a random order, were tested in one
experiment. For technical reasons, not all of the renal hemodynamic
parameters (RBF, CBF, OMBF, IMBF) were determined in each
experiment (see tables and figures for actual n values).
II. Effects of renal artery infusion of Ach before and after
L-NAME. In a separate series of seven rats, the responses to Ach
infusion at 60 mg/kg/h were first determined. Subsequently,
L-NAME, 1.8 mg/kg, was injected intravenously and, after stabiliza-
tion of BP and renal hemodynamics at a new level, the Ach infusion
tests were repeated. The dose of L-NAME used was 25% lower than
one inducing maximal depression of renal tissue NO, as determined
by us in a similar experimental setting.19
III. Effects of intramedullary infusion of Ach. Ach, dissolved in
isotonic saline, was infused into the renal medulla at 60 or 180 mg/
kg/h (in nine or 22 rats, respectively). The infusions lasted about
15 min, and were preceded and followed by solvent infusion periods
of 15–25 min. The volume infusion rate was always 1 ml/h; the saline
solvent infused at this rate did not change renal perfusion
parameters but occasionally caused a transient modest increase in
diuresis.
IV. Effects of intramedullary infusion of Ach before and after
L-NAME. Ach was first infused in nine rats at 180 mg/kg/h, as in
series III. After recovery, L-NAME was injected intravenously,
1.2 mg/kg and, after stabilization of hemodynamic parameters at a
new level, the Ach infusion test was repeated. An appropriate time
was subsequently allowed for stabilization, and another injection of
the same L-NAME dose was made, followed again by the Ach
infusion test.
V. Effects of intramedullary infusion of Cch. The procedure
was as in the Ach series except that Cch (Sigma Chemical Co., St
Louis, MO, USA), dissolved in isotonic saline, was infused at a rate
of 15 mg/kg/h (21 rats) and 30 or 60 mg/kg/h (20 rats). Two or three
doses, given at a random order, were tested in one experiment. The
dynamics of an increase in renal perfusion parameters, if any, and of
the recovery, were similar as observed with Ach infusions.
VI. Effects of intramedullary infusion of PGE2. The usual
procedure of intramedullary infusion was applied in 16 rats. PGE2
(Sigma Chemical Co., St Louis, MO, USA) was first dissolved in
96% ethanol and then in phosphate-buffered saline (pH 7.5), and
infused at a rate of 15 mg/kg/h. The PGE2 dose used was shown in
preliminary experiments to alter renal perfusion without affecting
BP. The solvent infused before and after PGE2 contained ethanol in
the same concentration (about 0.5%) as the PGE2 infusate. The
vehicle infusion per se did not change renal hemodynamics.
VII. Effects of intramedullary infusion of SNAP. In eight rats,
L-NAME was injected intravenously in the dose of 0.4 mg/kg, to
reduce endogenous NO synthesis. Subsequently, after stabilization of
BP and renal hemodynamic variables at a new level, SNAP (Sigma
Chemical Co., St Louis, MO, USA), an NO donor compound,
dissolved in isotonic saline, was infused at a rate of 15 or 30 mg/kg/h.
Statistics
The differences between mean values were evaluated by the classical
one-way analyses of variance followed by Student’s t-tests, paired or
unpaired, as required. For multiple comparisons, the Bonferroni
correction factor was used. The frequency distribution was evaluated
by w2 test with Yate’s correction. The standard error of the mean
(s.e.m.) was used as a measure of data dispersion, and Po0.05 was
accepted as the significance level.
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